Mt Hood 2025: Pre-Conference Workshop
A half-day workshop will be held prior to the conference. The workshops take place on Monday 23 June 2-5pm.
The workshop covers all aspects of building and using health-economic diabetes simulation models. The workshop will have no assumed knowledge and is intended to provide an overview of the field, including the latest developments.
​
Outline
​
Introduction to diabetes modelling
​
-
Brief History
-
How simulation models work
-
Constructing risk equations using individual data
-
Developing risk-factor equations
​
Quality of life and complications
​
-
Collection of Quality of life data: Case studies from UKPDS and ADVANCE studies
-
How often and what do we need to collect?
-
Heterogeneity in responses across regions
-
Should be using levels or changes in Quality of life?
-
Relationship between utility and mortality
-
Quality Adjusted Survival Models
-
Role of meta-analysis
​
Costs of treatments and complications
​
-
Changes in the price and expenditure of diabetes therapies: recent evidence
-
Options for collecting resource use information
-
Sources of costing data in other countries – Sweden, Australia, ADVANCE.
​
Future directions in modelling
​
-
Adapting models across settings
-
Calibration risk equations
-
Developing new equations – mortality following events - WA UKPDS example
-
LE calculators (Sweden & WA)
-
What can we learn from meta-models?
​
New Developments in Type 1 diabetes
​
-
Burden of the disease: Life expectancy gap in Sweden & Australia
-
How a hypo can impact on your life expectancy
-
Overview of a new Type 1 diabetes model
​
The future of diabetes simulation modelling
​
-
Capturing new treatments and interventions
-
Can we develop a universal model?
-
Software for simulation modelling
Speaker
​
Professor Philip Clarke was instrumental in the development of both versions of the UKPDS Outcomes Model. More recently he has been involved in the development of a comparable Type 1 diabetes simulation model using data from a large diabetes registry in Sweden. He has also been involved with the economic analyses of the major diabetes clinical trials including the UKPDS, FIELD and ADVANCE studies.
​
